The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1324
Saxagliptin (Onglyza) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Saxagliptin (Onglyza– Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes. Sitagliptin (Januvia) was the first.1

MECHANISM OF ACTION — Saxagliptin inhibits the activity of DPP-4, an enzyme that inactivates and degrades incretin hormones, cytokines and other peptides. Released in response to meals, incretin hormones potentiate insulin release and decrease glucagon production, lowering serum glucose concentrations.

CLINICAL STUDIES — Treatment-Naïve Patients – A double-blind, randomized, placebo-controlled, 24-week trial in 401 patients with type 2 diabetes not adequately controlled by diet and exercise (HbA1c 7-10%) found that saxagliptin 2.5 mg/day reduced HbA1c by 0.43% from baseline, 5 mg/day reduced it by 0.46% and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Saxagliptin (Onglyza) for Type 2 Diabetes
Article code: 1324a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian